Clinical trial
MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)
NCT00371007 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00371007 |
|---|---|
| Title | MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043) |
| Official title | MK0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks, Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks |
| Enrollment | 126 |
| Start date | Jun 1, 2004 |
| Primary completion | Apr 25, 2005 |
| Completion | Apr 25, 2005 |
| First posted | Sep 1, 2006 |
| Last update posted | Apr 4, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: